Sees Pro forma 2025 Synergized Adjusted EBITDA: $165M – $185M; DefenCath 2025 Revenue: $200M – $215M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix Inc. Advances in Infection Prevention with DEFENCATH® Study
- Cormedix Inc. Advances Pediatric Study on DefenCath® for Infection Prevention
- CorMedix Completes $150M Convertible Notes Offering
- CorMedix Inc. Earnings Call Highlights Strategic Growth
- CorMedix price target lowered to $17 from $20 at H.C. Wainwright